A Trial of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients Malignancies

Official Title

A Phase 1 Cohort Dose-Escalation Trial of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients With Advanced or Metastatic Solid Tumour Malignancies


TGFβ has profound local immunosuppressive and immunoexclusion effects in the tumour microenvironment that are integrally involved in the failure of immune checkpoint inhibitors in some tumours. Preclinical data in a variety of models strongly support the study of AVID200 in patients with treatment-refractory advanced and metastatic malignancies as an approach to reducing immunosuppression/exclusion and increasing the activity of immune checkpoint inhibitors.

Trial Description

Primary Outcome:

  • Incidence of Treatment-Emergent Adverse Events
TGFβ inhibits local anti-tumour immunity in the tumour microenvironment (TME) and also promotes the epithelial to mesenchymal transition (EMT) that enhances the metastatic potential of tumour cells. Cancer-associated fibroblasts (CAFs) are a critical constituent of the TME. As is the case for fibrosis in other settings, these cells are myofibroblast-like, and respond to and are activated by tumour-derived TGFβ. CAFs play a critical role in promoting EMT resulting in increased tumour cell migration and invasion as well as maintaining the TME to support tumour cell survival. The immunosuppressive role of TGFβ in the TME has been clearly demonstrated with the activation of CAFs being an important mechanism underlying immune cell exclusion. Exclusion of immune cells from tumours and local immunosuppression can both be reversed by AVID200 therapy.

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society